or the GIN. 40 vector-containing supernatant, 
hematopoietic growth factors, and protamine. (See 
Appendix B for details of transduction procedure) At 
the end of the 72 hour transduction period, the cells 
will be collected and cryopreserved. Aliquots will be 
removed for analysis as tabulated in Appendix C. 
5.2 Bone Marrow : If criteria are met as described in 
section 4.2, 70% of the processed marrow mononuclear 
cells will be immediately cryopreserved. The remaining 
30% will be incubated with the anti-CD34 murine 
monoclonal antibody 12.8 and then passed over the 
CellPro immunoadsorption column (see Appendix A for 
details of the procedure). The CD34+ enriched cell 
population will be cultured in vitro for 72 hours in 
the presence of either the LNL6 or the GIN. 40 vector- 
containing supernatant, hematopoietic growth factors, 
and protamine. (See Appendix B for details of the 
transduction procedure) Breast cancer marrows will be 
transduced with the GIN. 40 vector. Multiple myeloma 
and CML marrows will be transduced with LNL6 vector if 
GIN. 40 was used to transduce an individual patient's 
peripheral blood stem cells, or GIN. 40 if LNL6 was used 
to transduce an individual patient's peripheral blood 
stem cells. At the end of the 72 hour period, the 
cells will be collected and cryopreserved. Aliquots 
will be reoved for analysis as tabulated in Appendix C. 
5.3 Reinfusion : After high-dose conditioning therapy as 
described in the protocols, each patient's transduced 
and non-transduced bone marrow and peripheral blood 
cell fractions will be thawed at 37 degrees and 
infused. Monitoring and supportive care during the 
infusions will be as described in the original 
protocols .( Section 5.0 in Multiple Myeloma and CML 
protocols, section 6.10 in breast cancer protocol) 
5.4 Supportive Care : Post-transplantation supportive care 
and monitoring will be as described in the original 
protocols . 
6 . 0 ON-STUDY EVALUATION 
6.1 CD34-enriched and transduced bone marrow or peripheral 
blood cells will be analyzed for sterility, viability, 
CD3 4-expression, CFU-C, % transduction, and helper 
virus as tabulated in Appendix C. 
6.1 On study evaluation to assess hematopoietic function 
and disease status will be as described in the original 
Recombinant DNA Research, Volume 16 
[19] 
